Atezolizumab + Ipatasertib + Paclitaxel + Placebo for Atezolizumab + Placebo for Ipatasertib
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Triple-Negative Breast Cancer
Conditions
Triple-Negative Breast Cancer
Trial Timeline
Nov 25, 2019 → Feb 28, 2023
NCT ID
NCT04177108About Atezolizumab + Ipatasertib + Paclitaxel + Placebo for Atezolizumab + Placebo for Ipatasertib
Atezolizumab + Ipatasertib + Paclitaxel + Placebo for Atezolizumab + Placebo for Ipatasertib is a phase 3 stage product being developed by Roche for Triple-Negative Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT04177108. Target conditions include Triple-Negative Breast Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04177108 | Phase 3 | Completed |
Competing Products
20 competing products in Triple-Negative Breast Cancer